IT1148727B - Derivati di 4-fenil-ftalazine ad azione terapeutica - Google Patents

Derivati di 4-fenil-ftalazine ad azione terapeutica

Info

Publication number
IT1148727B
IT1148727B IT25206/80A IT2520680A IT1148727B IT 1148727 B IT1148727 B IT 1148727B IT 25206/80 A IT25206/80 A IT 25206/80A IT 2520680 A IT2520680 A IT 2520680A IT 1148727 B IT1148727 B IT 1148727B
Authority
IT
Italy
Prior art keywords
phtalazine
fenyl
derivatives
therapeutic action
therapeutic
Prior art date
Application number
IT25206/80A
Other languages
English (en)
Other versions
IT8025206A0 (it
Inventor
Hayashi Eisaku
Oishi Etsuo
Morinaka Yasuhiro
Mori Motokuni
Kanayama Toshiji
Original Assignee
Mitsubishi Yuka Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP13043479A external-priority patent/JPS5653660A/ja
Priority claimed from JP12464480A external-priority patent/JPS5748972A/ja
Application filed by Mitsubishi Yuka Pharma filed Critical Mitsubishi Yuka Pharma
Publication of IT8025206A0 publication Critical patent/IT8025206A0/it
Application granted granted Critical
Publication of IT1148727B publication Critical patent/IT1148727B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/34—Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heat Sensitive Colour Forming Recording (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
IT25206/80A 1979-10-09 1980-10-08 Derivati di 4-fenil-ftalazine ad azione terapeutica IT1148727B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP13043479A JPS5653660A (en) 1979-10-09 1979-10-09 4-phenylphthalazine derivative
JP12464480A JPS5748972A (en) 1980-09-10 1980-09-10 4-phenylphthalazine derivative

Publications (2)

Publication Number Publication Date
IT8025206A0 IT8025206A0 (it) 1980-10-08
IT1148727B true IT1148727B (it) 1986-12-03

Family

ID=26461284

Family Applications (1)

Application Number Title Priority Date Filing Date
IT25206/80A IT1148727B (it) 1979-10-09 1980-10-08 Derivati di 4-fenil-ftalazine ad azione terapeutica

Country Status (5)

Country Link
DE (1) DE3038166A1 (it)
FR (1) FR2468593A1 (it)
GB (1) GB2063249A (it)
IT (1) IT1148727B (it)
NL (1) NL8005411A (it)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60218377A (ja) * 1984-04-16 1985-11-01 Mitsubishi Yuka Yakuhin Kk ４−フエニルフタラジン誘導体及びそれを有効成分とする循環改善剤
EP0449203B1 (en) * 1990-03-30 1994-12-07 Mitsubishi Chemical Corporation 4-Phenylphthalazine derivatives
TW279162B (it) * 1991-09-26 1996-06-21 Mitsubishi Chem Corp
US5696159A (en) * 1994-08-03 1997-12-09 Cell Pathways, Inc. Lactone compounds for treating patients with precancerous lesions
US5776962A (en) * 1994-08-03 1998-07-07 Cell Pathways, Inc. Lactone compounds for treating patient with precancerous lesions
US6232312B1 (en) 1995-06-07 2001-05-15 Cell Pathways, Inc. Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
US6200980B1 (en) 1995-06-07 2001-03-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl purinone derivatives
US5874440A (en) * 1995-06-07 1999-02-23 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives
US6046216A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
US6262059B1 (en) 1995-06-07 2001-07-17 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with quinazoline derivatives
US6060477A (en) * 1995-06-07 2000-05-09 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives
EP0825187A1 (en) * 1996-08-22 1998-02-25 Takeda Chemical Industries, Ltd. Condensed pyridazinyl guanidines, their production and use
ATE236134T1 (de) 1996-12-18 2003-04-15 Neurogen Corp Isoquinolinamin und phtalazinamin derivate, die reagieren mit crf rezeptoren
GB9707693D0 (en) * 1997-04-16 1997-06-04 Smithkline Beecham Plc Novel method of treatment
CA2238283C (en) 1997-05-30 2002-08-20 Cell Pathways, Inc. Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
US5858694A (en) * 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions
US5852035A (en) * 1997-12-12 1998-12-22 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to substituted N- arylmethyl and heterocyclmethyl-1H-pyrazolo (3,4-B) quinolin-4-amines
IT1296984B1 (it) * 1997-12-19 1999-08-03 Zambon Spa Derivati ftalazinici inibitori della fosfodiesterasi 4
US6046199A (en) * 1998-01-14 2000-04-04 Cell Pathways, Inc. Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
US6410584B1 (en) 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
US5942520A (en) * 1998-01-27 1999-08-24 Cell Pathways, Inc. Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines
US5990117A (en) * 1998-04-15 1999-11-23 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
ITMI981671A1 (it) 1998-07-21 2000-01-21 Zambon Spa Derivati ftalazinici inibitori della fosfodisterasi 4
ITMI981670A1 (it) * 1998-07-21 2000-01-21 Zambon Spa Derivati ftalazinici inibitori della fosfodiesterasi 4
US6180629B1 (en) 1998-08-14 2001-01-30 Cell Pathways, Inc. [4,5]-Fused-1,3-disubstituted-1,2-diazine-6-one derivatives with nitrogen containing substitutents in position one for the treatment of neoplasia
US6124303A (en) * 1998-09-11 2000-09-26 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6130053A (en) * 1999-08-03 2000-10-10 Cell Pathways, Inc. Method for selecting compounds for inhibition of neoplastic lesions
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6025394A (en) 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
US6555547B1 (en) 2000-02-28 2003-04-29 Cell Pathways, Inc. Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative
US6569638B1 (en) 2000-03-03 2003-05-27 Cell Pathways, Inc Method for screening compounds for the treatment of neoplasia
US6479493B1 (en) 2001-08-23 2002-11-12 Cell Pathways, Inc. Methods for treatment of type I diabetes
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CA2684965A1 (en) * 2007-04-23 2008-10-30 Novartis Ag Phthalazine and isoquinoline derivatives with s1p receptor modulating activities
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2688161C (en) 2007-06-04 2020-10-20 Kunwar Shailubhai Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP2011528375A (ja) 2008-07-16 2011-11-17 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
CA2812088A1 (en) * 2010-09-14 2012-03-22 Exelixis, Inc. Phtalazine derivatives as jak1 inhibitors
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012118972A2 (en) 2011-03-01 2012-09-07 Synegy Pharmaceuticals Inc. Process of preparing guanylate cyclase c agonists
AU2014218599C1 (en) 2013-02-25 2018-09-06 Bausch Health Ireland Limited Guanylate cyclase receptor agonists for use in colonic cleansing
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CN105764916B (zh) 2013-06-05 2021-05-18 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
IL280864B2 (en) 2013-08-09 2024-03-01 Ardelyx Inc Compounds and methods for inhibiting phosphate transport
EP3157520B1 (en) 2014-06-23 2019-09-04 Celgene Corporation Apremilast for the treatment of a liver disease or a liver function abnormality
CN114340631A (zh) 2019-05-21 2022-04-12 阿德利克斯股份有限公司 用于降低患者的血清磷酸盐的组合
US11319319B1 (en) * 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1303061A (it) * 1969-05-03 1973-01-17

Also Published As

Publication number Publication date
NL8005411A (nl) 1981-04-13
FR2468593A1 (fr) 1981-05-08
GB2063249A (en) 1981-06-03
IT8025206A0 (it) 1980-10-08
DE3038166A1 (de) 1981-05-21

Similar Documents

Publication Publication Date Title
IT1148727B (it) Derivati di 4-fenil-ftalazine ad azione terapeutica
IT1132189B (it) Derivati ammidici ad azione antiipertensiva
IT1192347B (it) Derivati di alchilendiamine
IT1105411B (it) Derivati di ciclosano
IT1098858B (it) Derivati di immidazoli
IT1098276B (it) Derivati di trifenilalcheni
NO802946L (no) Imidazo-diazepinderivater
FI800910A (fi) Farmaceutiskt anvaendbara 4-amino-3-kinolinkarboxylsyror och -estrar
IT1101613B (it) Derivati di 2,6-diamminonebularine ad azione farmacolosica
IT1132532B (it) Fosfodiesteri di nucleosidi-corticosteroidi citotossici
IT1235424B (it) Derivati del beta-3-ammino-nortropano
IT8022265A0 (it) Derivati di alchil-chetoesopiranosidi.
IT1099026B (it) Composti ad azione analgesica comprendenti derivati di azacicloalcani
IT1127231B (it) Derivati spiro-policiclicimidazolidinadionici
IT8020502A0 (it) Derivati di 9-amminoalchilfluorene ad azione farmaceutica.
IT1114222B (it) Derivati 4-ammino-2-piperidinochinazolinici ad azione terapeutica
IT1122489B (it) Derivati di cloroambucile
IT1096276B (it) Derivati di benzimmidazolo
IT1110540B (it) Derivati di alcanolammine
IT1092333B (it) Derivati di ossadiazol-pirimidine
IT1140774B (it) Isonicotinoil derivati di amminoacidi ad azione erbicida
IT1188839B (it) Derivati di arabino-furanosil-citosina
IT1111174B (it) Derivati di piridazione
IT1095493B (it) Derivati di chinazoline
IT1131195B (it) Derivati di benzodiazepine